Previous Article | Next Article ![]()
Molecular and Cellular Biology, October 1999, p. 7287-7287, Vol. 19, No. 10
Tumor-Specific PAX3-FKHR Transcription Factor, but Not
PAX3, Activates the Platelet-Derived Growth Factor Alpha Receptor
Cardiovascular Division, Department of Medicine, University of
Pennsylvania, Philadelphia, Pennsylvania 19104, and Center for
Molecular Biology of Oral Diseases, University of Illinois at
Chicago, Chicago, Illinois 60612 and
Volume 18, no. 7, p. 4118-4130, 1998, and volume 19, no. 1, p.
594-601, 1999: Dr. Thomas B. Friedman and Thomas Barber from the
National Institute on Deafness and Other Communication Disorders at the
National Institutes of Health have alerted us that the cDNA clone of
the Pax3-FKHR transcription factor used in experiments published in the
Molecular and Cellular Biology articles listed above was
incompletely described. As indicated in the Epstein et al. article, the
plasmid encoding Pax3-FKHR is a mouse-human hybrid composed of murine
Pax3 (GenBank accession no. X59358, nucleotides 313 to 719) encoding an
amino acid sequence identical to that of human PAX3, followed by human
PAX3-FKHR (GenBank accession no. U02368, nucleotides 471 to 2556), and
a sequence encoding a 9-residue carboxy-terminal hemagglutinin (HA)
epitope tag. The sequence of this HA tag (YDVPDYASL) differs from the
common HA epitope (YPYDVPDYA) and corresponds to 9 residues of the
12-residue peptide used to raise commercially available anti-HA
antibodies (Covance Research Products Inc., Richmond, Calif.). The
YDVPDYASL tag is also recognized by the commercially available anti-HA antibodies.
Both the murine and human Pax3 full-length cDNAs contain three ATG
codons in frame. We are not aware of any published or preliminary data
describing the amino-terminal sequence of either Pax3 or PAX3-FKHR in
vivo. If all three ATGs are used in vivo, either in normal development
or in rhabdomyosarcoma, the proteins would differ by 10 or 11 amino-terminal residues. The chimeric cDNA used in our studies and in
those of others (Fredericks et al., Mol. Cell. Biol.
15:1522-1535, 1995; Scheidler et al., Proc. Natl. Acad.
Sci. USA 93:9805-9809, 1996) begins at the second ATG. To
date, results from our laboratories independently confirm that the
presence or absence of the first ATG codon or of the carboxy-terminal
HA tag in the context of Pax3-FKHR does not alter the results and
conclusions reported in our studies.
We will make the mouse-human PAX3-FKHR cDNA construct containing the
first ATG available upon request. The complete annotated sequence has
been submitted to GenBank under accession no. AF178854.
0270-7306/99
Copyright © 1999, American Society for Microbiology. All rights reserved.
AUTHOR'S CORRECTION
Molecular and Cellular Biology, October 1999, p. 7287-7287, Vol. 19, No. 10
0270-7306/99
Copyright © 1999, American Society for Microbiology. All rights reserved.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»